• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Study on Development of Novel Cancer Vaccine Using Hybrid Liposomes

Research Project

Project/Area Number 25420842
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Biofunction/Bioprocess
Research InstitutionSojo University

Principal Investigator

GOTO Koichi  崇城大学, 生物生命学部, 教授 (30279377)

Co-Investigator(Kenkyū-buntansha) 上岡 龍一  崇城大学, 生物生命学部, 研究員 (70099076)
Project Period (FY) 2013-04-01 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywordsがん / ワクチン / リポソーム / 免疫 / 癌
Outline of Final Research Achievements

In this study, we examined the induction effects of hybrid liposomes (HL-MUC-1/mB7-1) composed of phospholipids (DMPC) and nonionic surfactants (Tween 80) including synthetic mucin MUC-1 antigen peptides and recombinant mB7-1 membrane proteins on the cancer immunotherapy in vitro and in vivo. CD8+ T cells from the mice intravenously administrated HL-MUC-1/mB7-1 had a tendency to increase the cytotoxicity to the breast cancer cells in vitro, and the prolonged survival was observed in mice implanted with breast cancer cells after the administration of HL-MUC1/mB7-1, suggesting the possibility of novel cancer vaccine using hybrid liposomes.

Report

(5 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Research-status Report
  • 2014 Research-status Report
  • 2013 Research-status Report

URL: 

Published: 2014-07-25   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi